FAKTOR-OPTIONSSCHEIN - NOVONESIS B Stock

Certificat

DE000MA8B170

Real-time Bid/Ask 09:06:50 2024-05-21 am EDT
0.27 EUR / 0.28 EUR -11.29% Intraday chart for FAKTOR-OPTIONSSCHEIN - NOVONESIS B
Current month+81.29%
1 month+81.29%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-21 0.27 -12.90%
24-05-20 0.31 0.00%
24-05-17 0.31 +6.90%
24-05-16 0.29 +7.41%
24-05-15 0.27 +8.43%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 07:49 am EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying NOVONESIS A/S
Issuer Morgan Stanley
WKN MA8B17
ISINDE000MA8B170
Date issued 2021-08-02
Strike 348.4 kr
Maturity Unlimited
Parity 38.61 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.3
Lowest since issue 0.046
Spread 0.01
Spread %3.57%

Company Profile

Novonesis A/S (formerly Novozymes A/S) is the world's leading producer of enzymes and microorganisms for industrial companies. Net sales break down by market as follows: - industry of cleaning and household maintenance products (28.5%); - bioenergy (24.8%); - food industry and human health (22.1%); - technical and cereal industries (12.8%): microorganisms used in the field of wastewater treatment, technical enzymes intended for the textile, leather, pulp and paper industries; - agriculture and animal feed industry (11.8%): enzymes used to improve the productivity and digestion of certain foods. Net sales are geographically distributed as follows: Denmark (1.3%), Europe/Middle East/Africa (33.5%), North America (33.9%), Asia/Pacific (18.5%) and Latin America (12.8%).
Sector
-
More about the company

Ratings for Novonesis A/S

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Novonesis A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
435.4 DKK
Average target price
437.4 DKK
Spread / Average Target
+0.47%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW